Onsdag 28 Oktober | 18:12:50 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

XVIVO - Firing on more cylinders

2023-09-18 08:55:00

Redeye updates our outlook after the SEK 440m (gross) directed rights issue priced at SEK 275, will allow XVIVO to push the Liver Assist and the Heart solution onto the US market and rapidly ramp up the production capacity for recurring margin sales. In our view, this is positive, considering the long sales runway, short pay-back times and XVIVO's better use of its existing toolbox. Our base case is SEK 450 (Bull 950, Bear 105).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/